dc.creator | Ioannou, M. | en |
dc.creator | Paraskeva, E. | en |
dc.creator | Baxevanidou, K. | en |
dc.creator | Simos, G. | en |
dc.creator | Papamichali, R. | en |
dc.creator | Papacharalambous, C. | en |
dc.creator | Samara, M. | en |
dc.creator | Koukoulis, G. | en |
dc.date.accessioned | 2015-11-23T10:30:28Z | |
dc.date.available | 2015-11-23T10:30:28Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 11070625 | |
dc.identifier.uri | http://hdl.handle.net/11615/28605 | |
dc.description.abstract | Colorectal cancer (CRC) is the third most common cancer worldwide and despite the abundance of molecular pathways and markers continually being reported, the mortality rates remain high. Hypoxia inducible f actor lalpha (HIF-1a) plays a major role in the response of tumors to hypoxia, and contributes to tumor aggressiveness, invasiveness and resistance to radiotherapy and chemotherapy. Targeting HIF-la is an attractive strategy, with the potential for disrupting multiple pathways crucial for tumor growth. In the current study, HIF-la immunohistochemical expression in CRC is reviewed along with the relation to clinical outcome and prognosis. In addition, the significant correlation of HIF-la to vascular endothelial growth factor (VEGF) expression is reported, as well as the possible role of HIF-la in predicting the therapeutic response to anti-EGFR therapies. Herein, an overview of the HIF-la expression in CRC is presented. This review delineates the crucial role that HIF-1a plays in carcinogenesis, tumor angiogenesis and cancer progression. The evaluation of HIF-la in patient biopsies could be useful as a prognostic and/or predictive biomarker in personalized cancer treatment. | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84938676098&partnerID=40&md5=0aaa66e0402c055cc545d33a49367eac | |
dc.subject | Angiogenesis | en |
dc.subject | Colorectal carcinoma | en |
dc.subject | HIF-1α | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Prognosis | en |
dc.subject | APC protein | en |
dc.subject | B Raf kinase | en |
dc.subject | beta catenin | en |
dc.subject | cetuximab | en |
dc.subject | erlotinib | en |
dc.subject | gefitinib | en |
dc.subject | hypoxia inducible factor 1alpha | en |
dc.subject | K ras protein | en |
dc.subject | panitumumab | en |
dc.subject | vasculotropin | en |
dc.subject | vasculotropin receptor 2 | en |
dc.subject | von Hippel Lindau protein | en |
dc.subject | angiogenesis inhibitor | en |
dc.subject | tumor marker | en |
dc.subject | cancer cell | en |
dc.subject | cancer growth | en |
dc.subject | cancer prognosis | en |
dc.subject | cell hypoxia | en |
dc.subject | colon carcinogenesis | en |
dc.subject | colon polyposis | en |
dc.subject | disease association | en |
dc.subject | drug response | en |
dc.subject | gene overexpression | en |
dc.subject | human | en |
dc.subject | molecularly targeted therapy | en |
dc.subject | neovascularization (pathology) | en |
dc.subject | protein expression | en |
dc.subject | Review | en |
dc.subject | signal transduction | en |
dc.subject | tumor microenvironment | en |
dc.subject | animal | en |
dc.subject | Colorectal Neoplasms | en |
dc.subject | gene expression regulation | en |
dc.subject | genetics | en |
dc.subject | metabolism | en |
dc.subject | pathology | en |
dc.subject | vascularization | en |
dc.subject | Angiogenesis Inhibitors | en |
dc.subject | Animals | en |
dc.subject | Gene Expression Regulation, Neoplastic | en |
dc.subject | Humans | en |
dc.subject | Hypoxia-Inducible Factor 1, alpha Subunit | en |
dc.subject | Molecular Targeted Therapy | en |
dc.subject | Neovascularization, Pathologic | en |
dc.subject | Tumor Markers, Biological | en |
dc.title | HIF-1α in colorectal carcinoma: Review of the literature | en |
dc.type | journalArticle | en |